Bolden Therapeutics is developing first-in-class therapeutics to increase neurogenesis (the formation of new brain cells) and improve outcomes in neurological disease.
Bolden has established proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory in a proprietary mouse model targeting a novel and specific signaling pathway.
Bolden is developing multiple therapeutic modalities in parallel, leading with exon-skipping antisense oligonucleotides.
Due to the fundamental nature of neurogenesis, there are several potential clinical applications for neurogenesis-promoting therapies, such as those we aim to develop.
Bolden has a strong and growing team with complementary expertise.
Neurogenesis is the formation of new neurons from neural stem cells (NSCs). It is an endogenous process that has been observed throughout life into advanced age. NSCs reside in at least two regions of the adult brain: the dentate gyrus of the hippocampus and the subventricular zone, which lines the lateral ventricles. Additional information about neurogenesis, Alzheimer's disease, and drug development can be found in our team’s publications.
PROVIDENCE, R.I., PRNewswire — Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation to present at the 4th Annual Oligonucleotides for CNS Summit on July 10th in Boston, MA.
PROVIDENCE, RI. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system illnesses such as Alzheimer’s disease, today announced the closing of their $1.5M pre-seed convertible note financing. This financing provides important support to enable Bolden to advance its preclinical development of antisense oligonucleotides to promote neurogenesis. The round was led by Resolute Venture Partners, and included investments from Slater Technology Fund, Lifespan Vision Ventures, and multiple angel investors.
PROVIDENCE, RI and BOSTON, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation to present at the 3rd Annual Oligonucleotides for CNS Summit on June 6th-8th in Boston, MA.
PROVIDENCE, RI and BOSTON, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their upcoming presentation at the BIO International Convention during Jun 5th-8th in Boston, MA.
CAMBRIDGE, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Research and Entrepreneurial Development Immersion (REDI) Small Business Innovative Research (SBIR) grant for $406,466 from the National Institute on Aging (NIA) of the National Institutes of Health.
CAMBRIDGE, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Small Business Innovative Research (SBIR) grant for $497,500 from the National Institute on Aging (NIA) of the National Institutes of Health.
PROVIDENCE, RI & CAMBRIDGE, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment ofCNS diseases such as Alzheimer’s disease, today announced receiving a $500,000 Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging of the National Institutes of Health.
PROVIDENCE, RI. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment of CNS diseases such as Alzheimer’s and ischemic stroke, today announced being awarded the Biogen-LabCentral Golden Ticket.